Gastroenterology · General Practice · 2 h ago
AGA–AASLD guideline addresses diagnosis and management of primary biliary cholangitis
A multidisciplinary AGA–AASLD panel developed six recommendations for adults with primary biliary cholangitis (PBC), using systematic reviews and GRADE methods. The guidance covers diagnosis, first- and second-line treatment, risk assessment, pruritus and prevention of recurrence after liver transplantation; certainty of evidence ranged from moderate to very low.
- Guideline makes six recommendations for adults with PBC.
- UDCA is identified as first-line therapy.
- Evidence certainty ranges from moderate to very low.
- Recommendations cover pruritus and post-transplant recurrence.
The American Gastroenterological Association (AGA) and American Association for the Study of Liver Diseases (AASLD) convened an 11-member multidisciplinary panel to develop recommendations for adults with PBC. The panel conducted systematic reviews for six prioritized clinical questions and used the GRADE framework to assess evidence and develop recommendations. AGA provided funding; no industry funding was accepted for guideline development.
The six recommendations address testing for PBC-specific antinuclear antibodies when PBC is suspected despite negative antimitochondrial antibodies; ursodeoxycholic acid (UDCA) as first-line therapy; liver stiffness measurement for prognostication; peroxisome proliferator–activated receptor agonists for inadequate response or intolerance to UDCA; linerixibat for moderate-to-severe pruritus; and UDCA prophylaxis after liver transplantation to reduce recurrence. The guideline’s decision tool defines inadequate response as failure to achieve serum alkaline phosphatase below 1.5–1.67 times the upper limit of normal and normal total bilirubin after 12 months.
The guidance is intended to support shared, individualized decisions rather than serve as a rigid standard. Evidence certainty ranged from moderate to very low, and the recommendations do not establish that every patient will benefit. The panel emphasizes early diagnosis, assessment of treatment response, risk-based escalation and symptom management.
In practice
For adults with PBC, the guideline provides a framework for antibody testing when antimitochondrial antibodies are negative, UDCA as first-line treatment, prognostic use of liver stiffness, and treatment escalation when response to UDCA is inadequate or treatment is not tolerated. It also addresses linerixibat for moderate-to-severe pruritus and UDCA prophylaxis after transplantation. These recommendations support clinical decision-making but do not mandate a uniform approach; evidence certainty ranges from moderate to very low, so applicability should be considered for each patient.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Hepatology: AASLD AGA clinical Practice Guideline on management of primary biliary cholangitis ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.